Patrick Durez, ACR 2022: Adverse event reporting in rheumatoid arthritis clinical trials – an analysis of long-term filgotinib integrated safety data
Different methods such as exposure-adjusted incidence rates and exposure-adjusted event rates are used to report adverse events in rheumatoid arthritis (RA) clinical trials, this study compared different methodologies of reporting in long-term filgotinib integrated safety data. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) around the aims, design and findings of the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA.‘ (Abstract number: 0278) was presented at the ACR Convergence, November 10–14, 2022.
- Could you explain the terms exposure-adjusted incidence rates (EAIRs) and exposure-adjusted event rates (EAERs) in reporting treatment-emergent adverse events in clinical trials? (0:19)
- Which of these is most commonly used in RA studies and how can this affect the outcome evaluation? (1:01)
- What were the aims and design of your study? (1:37)
- What were the findings of the study? (2:06)
- What is the key take-home message for future clinical trial design? (2:40)
Disclosures: Patrick Durez has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!